Deciphera Pharmaceuticals LLC

230 articles about Deciphera Pharmaceuticals LLC

• Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

  11/29/2023

  Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 1:30 PM ET.

• Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - November 7, 2023

  11/7/2023

  Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.

• Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results

  10/30/2023

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

• Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT)

  10/30/2023

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced positive top-line results from the MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT not amenable to surgery.

• Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 15, 2023

  9/15/2023

  Deciphera Pharmaceuticals, Inc. announced that in connection with the hiring of Dashyant Dhanak, Ph.D., Executive Vice President and Chief Scientific Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 65,900 shares of Deciphera’s common stock, 65,900 restricted stock units and a special grant of 75,000 RSUs to Dr.

• Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  8/18/2023

  Deciphera Pharmaceuticals, Inc. announced that in connection with the hiring of Kevin Brodbeck, Senior Vice President and Chief Technical Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 89,200 shares of Deciphera’s common stock, 44,600 restricted stock units and a special grant of 15,000 RSUs to Mr. Brodbeck with a grant date of August 15, 2023.

• Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

  8/9/2023

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

  8/3/2023

  Deciphera Pharmaceuticals, Inc. announced that the Company’s Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company.

• Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023

  8/2/2023

  Deciphera Pharmaceuticals, Inc. today announced that it will report its second quarter 2023 financial results on Wednesday, August 9, 2023.

• Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

  5/25/2023

  Deciphera Pharmaceuticals, Inc. announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023.

• Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - May 23, 2023

  5/23/2023

  Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.

• Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

  5/8/2023

  Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New York, NY.

• Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results

  5/3/2023

  Deciphera Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023

  4/26/2023

  Deciphera Pharmaceuticals, Inc. today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023.

• Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days

  4/19/2023

  Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 AM ET.

• Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients & FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 & 17/18

  3/14/2023

  Deciphera Pharmaceuticals, Inc. announced that QINLOCK® has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology as a preferred regimen for second-line gastrointestinal stromal tumor patients intolerant to sunitinib.

• Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

  3/14/2023

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023.

• Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT

  3/1/2023

  Deciphera Pharmaceuticals, Inc. today announced the completion of enrollment in the pivotal Phase 3 MOTION study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT) not amenable to surgery. Deciphera expects to report top-line results in the fourth quarter of 2023.

• Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - February 27, 2023

  2/27/2023

  Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.

• Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results

  2/7/2023

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.